Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2012 1
2018 1
2019 1
2020 2
2021 2
2022 3
2023 5
2024 7
2025 10
2026 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Lipoprotein(a): a Case for Universal Screening in Youth.
Alankar A, Brar PC, Kohn B. Alankar A, et al. Curr Atheroscler Rep. 2023 Aug;25(8):487-493. doi: 10.1007/s11883-023-01120-3. Epub 2023 Jul 5. Curr Atheroscler Rep. 2023. PMID: 37405555 Review.
PURPOSE OF REVIEW: Lipoprotein(a) has emerged as a strong independent risk factor for cardiovascular disease. ...Lp(a) measurement included as part of routine universal lipid screening in youth would identify those children at risk of ASCVD and enable …
PURPOSE OF REVIEW: Lipoprotein(a) has emerged as a strong independent risk factor for cardiovascular disease. ...Lp(a) measure …
Lipoprotein(a) at a "Tipping Point": case to move to universal screening.
Bhatia HS. Bhatia HS. Am J Prev Cardiol. 2025 Aug 22;23:101274. doi: 10.1016/j.ajpc.2025.101274. eCollection 2025 Sep. Am J Prev Cardiol. 2025. PMID: 40918925 Free PMC article. Review.
Elevated lipoprotein(a) [Lp(a)] is well established as a common risk factor for atherosclerotic cardiovascular disease (ASCVD). ...However, Lp(a) remains very underrecognized as a cardiovascular risk factor with low rates of testing. In this article, the case for …
Elevated lipoprotein(a) [Lp(a)] is well established as a common risk factor for atherosclerotic cardiovascular disease (ASCVD) …
Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study.
Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, Reeskamp LF, Stroes ESG, Hovingh GK, Boekholdt SM, Ridker PM. Kraaijenhof JM, et al. Eur Heart J. 2025 Oct 14;46(39):3875-3884. doi: 10.1093/eurheartj/ehaf209. Eur Heart J. 2025. PMID: 40167249 Free PMC article.
BACKGROUND AND AIMS: Recent data from a large American cohort of women strongly support universal one-time screening for LDL cholesterol, high-sensitivity C-reactive protein (hsCRP), and lipoprotein(a) [Lp(a)] in primary prevention. ...These data repli …
BACKGROUND AND AIMS: Recent data from a large American cohort of women strongly support universal one-time screening for LDL c …
High lipoprotein(a): Actionable strategies for risk assessment and mitigation.
Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. Reyes-Soffer G, et al. Am J Prev Cardiol. 2024 Apr 3;18:100651. doi: 10.1016/j.ajpc.2024.100651. eCollection 2024 Jun. Am J Prev Cardiol. 2024. PMID: 38646021 Free PMC article. Review.
High levels of lipoprotein(a) [Lp(a)] are causal for atherosclerotic cardiovascular disease (ASCVD). Lp(a) is the most prevalent inherited dyslipidemia and strongest genetic ASCVD risk factor. ...The evolving nature of clinical guidelines and consensus statements re …
High levels of lipoprotein(a) [Lp(a)] are causal for atherosclerotic cardiovascular disease (ASCVD). Lp(a) is the most prevale …
Lipoprotein(a) and coronary artery disease: The need for universal screening - A case-based review.
Ngo NYN, Villavaso CD, Orakwue CJ, Rowalt WZ, Roberts M, Ferdinand KC. Ngo NYN, et al. Am Heart J Plus. 2025 Jun 1;56:100560. doi: 10.1016/j.ahjo.2025.100560. eCollection 2025 Aug. Am Heart J Plus. 2025. PMID: 40535317 Free PMC article. Review.
DISCUSSION: The global prevalence of elevated Lp(a) >50 mg/dL is around 1.43 billion. Elevated lipoprotein(a) is now recognized, based on the preponderance of the evidence, by several international scientific statements as an independent risk factor for ASCVD, in …
DISCUSSION: The global prevalence of elevated Lp(a) >50 mg/dL is around 1.43 billion. Elevated lipoprotein(a) is now recogn …
Lipoprotein (a) in Youth.
McNeal CJ, Peterson AL. McNeal CJ, et al. 2023 Apr 19. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2023 Apr 19. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 27809431 Free Books & Documents. Review.
Lipoprotein (a) [Lp(a)] represents a class of lipoproteins with structural similarity to low-density lipoprotein (LDL). ...The usual pitfalls of extrapolating from adult data may be less problematic for Lp(a) given that the gene is fully expressed at a very young ag …
Lipoprotein (a) [Lp(a)] represents a class of lipoproteins with structural similarity to low-density lipoprotein (LDL). ...The …
Lipoprotein(a) screening: Balancing benefits and challenges in clinical decision-making.
Crain N. Crain N. JAAPA. 2026 Jun 1;39(6):16-21. doi: 10.1097/01.JAA.0000000000000361. Epub 2026 May 26. JAAPA. 2026. PMID: 42190088 Review.
Lipoprotein(a) (Lp(a)) is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), independent of traditional risk factors such as low-density lipoprotein cholesterol (LDL-C). Major societies now broadly recognize Lp(a) as an independent …
Lipoprotein(a) (Lp(a)) is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), independent of …
Evolving guidelines on lipoprotein(a).
Boffa MB, Koschinsky ML, Hegele RA. Boffa MB, et al. Curr Opin Lipidol. 2025 Dec 1;36(6):300-309. doi: 10.1097/MOL.0000000000001016. Epub 2025 Oct 22. Curr Opin Lipidol. 2025. PMID: 41190669 Review.
PURPOSE OF REVIEW: Elevated plasma lipoprotein(a) [Lp(a)] is a causal and independent risk factor for atherosclerotic cardiovascular disease and an emerging therapeutic target. ...Guidelines and statements have increasingly recommended universal screening …
PURPOSE OF REVIEW: Elevated plasma lipoprotein(a) [Lp(a)] is a causal and independent risk factor for atherosclerotic cardiova …
Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening.
Clair V, Zirille FM, Gill E. Clair V, et al. Am J Prev Cardiol. 2025 Feb 14;21:100945. doi: 10.1016/j.ajpc.2025.100945. eCollection 2025 Mar. Am J Prev Cardiol. 2025. PMID: 40103685 Free PMC article. Review.
Lipoprotein(a) [Lp(a)] is a genetically inherited, independent risk factor for cardiovascular disease (CVD), affecting approximately 20-25% of the global population. ...Our findings support the integration of Lp(a) screening into routine cardiovascular risk a …
Lipoprotein(a) [Lp(a)] is a genetically inherited, independent risk factor for cardiovascular disease (CVD), affecting approxi …
Pediatric Dyslipidemia.
Gujral J, Gupta J. Gujral J, et al. 2024 Dec 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2024 Dec 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 36256753 Free Books & Documents.
An abnormal test should be followed by a repeat lipid profile done two weeks to 3 months later for confirmation. Screening for Dyslipidemia Universal Screening: Current guidelines recommend universal screening in the pediatric age group between …
An abnormal test should be followed by a repeat lipid profile done two weeks to 3 months later for confirmation. Screening for Dysli …
48 results